App-Quantinova.ai

EXPRESSION OF SERUM B CELL ACTIVATING FACTOR FROM THE TUMOR NECROSIS FACTOR FAMILY (BAFF) AND OF PROLIFERATION-INDUCING LIGAND (APRIL) IN PATIENTS WITH UNTREATED SYSTEMIC LUPUS ERYTHEMATOSUS

T. Panafidina - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

THE EFFICACY OF HYDROXYCHLOROQUINE FOR OBSTETRICAL OUTCOME IN ANTI-PHOSPHOLIPID SYNDROME: DATA FROM A EUROPEAN MULTICENTER RETROSPECTIVE STUDY

A. Mekinian - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ASSESSMENT OF THE IMPLEMENTATION OF THE REVISED RECOMMENDATIONS FOR SCREENING OF HYDROXYCHLOROQUINE RETINOPATHY IN THE CLINICAL PRACTICE OF OPTHALMOLOGISTS AND RHEUMATOLOGISTS

J. Wollman - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

RITUXIMAB THERAPY IN PATIENTS WITH REFRACTORY SKIN MANIFESTATION OF LUPUS ERYTHEMATOSUS DURING LONG-TERM FOLLOW-UP

M. Tsanyan - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

HOW WE ARE TREATING OUR SYSTEMIC PATIENTS WITH PRIMARY SJOGREN SYNDROME? ANALYSIS OF 1120 PATIENTS (GEAS-SS SPANISH REGISTRY)

H. Gheitasi - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sjogren's syndrome

Hydroxychloroquine

IMMUNOSUPPRESSIVE TREATMENT IN PATIENTS WITH PRIMARY SJOGREN SYNDROME (PSS)

G. Crespo Amaya - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Peripheral neuropathy

Hydroxychloroquine

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS OF SJOGRE-S SYNDROME USING A U.S. MANAGED CARE PRESCRIPTION CLAIMS DATABASE

J. Birt - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

EFFICACY AND SAFETY OF RITUXIMAB IN THE TREATMENT OF NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS DURING LONG-TERM FOLLOW-UP

M. Tsanyan - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Neuropsychiatric systemic lupus erythematosus

Hydroxychloroquine

PODOCYTIC ABNORMALITIES IN SLE PARALLEL MECHANISM AFFECTING KIDNEY

M. Vankalakunti - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Focal segmental glomerulosclerosis

Hydroxychloroquine

EFFICACY OF HYDROXYCHLOROQUINE IN PRIMARY HAND OSTEOARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

N. Basoski - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

Hydroxychloroquine

SARCOaDOSIS: OSTEOARTICULAR INVOLVEMENT 57 CASES

K. Echchilali - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Spondyloarthritis

Hydroxychloroquine

NO INCREASED RISK OF CONGENITAL MALFORMATIONS AFTER PRECONCEPTION PATERNAL EXPOSURE TO DMARDS

M. Wallenius - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital anomalies

Hydroxychloroquine

OMERACT METHOD OF COMBINED REPORTING OF BENEFIT AND HARM APPLIED TO THE TEAR TRIAL

M. Boers - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

FEWER PATIENTS ON BIOLOGICALS AND BETTER FUNCTIONAL ABILITY TWO YEARS AFTER INDUCTION THERAPY WITH COMBINATION DMARD THERAPY VERSUS METHOTREXATE MONOTHERAPY

M. Kuijper - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

PROLONGED ASSUMPTION OF HCQ IS ASSOCIATED WITH LONGER SURVIVAL IN SLE

M. Fredi - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

IMPROVING PATIENT UNDERSTANDING OF COMBINATION DMARD THERAPY USING PICTORIAL LEAFLETS

A. Ahmed - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

Hydroxychloroquine

CHANGING PATTERNS IN PRESCRIBING IN RHEUMATOID ARTHRITIS

A. Mian - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN UK PRIMARY CARE: SEVERITY AT ONSET AND PROGRESSION OVER TIME USING THE UK CLINICAL PRACTICE RESEARCH DATALINK

A. L. Nightingale - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

RETROSPECTIVE STUDY OF THE CAUSES OF HOSPITALIZATIONS AND MORTALITY OF RHEUMATOLOGICAL INPATIENTS IN SINGAPORE GENERAL HOSPITAL OVER 10 YEARS

W. W. S. Fong - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Antiphospholipid syndrome

Hydroxychloroquine

COMPILING AND EVALUATING EVIDENCE-BASED ALGORITHMS FOR THE MONITORING OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING DISEASE MODIFYING ANTIRHEUMATIC DRUGS AND BIOLOGICAL AGENTS

J. Vella - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Filters

1151 Abstracts